In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology. Overall survival was similar in both treatment arms and the side effect profile was consistent with that expected for sunitinib and everolimus.

Read more here